Arca
Skip to content

Myeloproliferative neoplasms

Drug research and approvals for myeloproliferative neoplasms: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 295 studies of myeloproliferative neoplasms are recruiting on ClinicalTrials.gov, and Health Canada has authorized 11 drug trials for it since 2013.

  • Recruiting worldwide: 295
  • Trials authorized in Canada: 11
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 295 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 11; search them all in Canada trials
May 22, 2026A phase 1, open-label, multicenter study of inca036978 in participants with myeloproliferative neoplasmsINCA036978 / JAKAVIIncyte CorporationOngoing
Nov 18, 2025A phase 1, open-label, multicenter study of incb160058 in participants with myeloproliferative neoplasmsINCB160058 / RUXOLITINIBIncyte CorporationOngoing
May 10, 2024An open-label, multicenter, extension study for patients previously enrolled in studies with pelabresibPELABRESIB (CPI-0610)CONSTELLATION PHARMACEUTICALS INC.Pending
Nov 16, 2023A phase 1, open-label, multicenter study of inca033989 administered as a monotherapy or in combination with ruxolitinib in participants with myeloproliferative…INCA033989 / RUXOLITINIBIncyte CorporationOngoing
Sep 7, 2023Protocol 10538, venetoclax in combination with astx727, an all-oral therapy for chronic myelomonocytic leukemia and other mds/mpn with excess blasts…ASTX727 (CEDAZURIDINE-DECITABINE)/ VENETOCLAXUNIVERSITY HEALTH NETWORKOngoing
May 31, 2023A phase 1, open-label, multicenter, dose escalation study of prt1419 injection as monotherapy or in combination with azacitidine or venetoclax in patients with…PRT1419 / VENETOCLAX / AZACITIDINEPRELUDE THERAPEUTICSClosed
Dec 21, 2021Venetoclax and azacitidine combination therapy for patients with accelerated or blast phase bcr-abl negative myeloproliferative neoplasm (vaamp)VENETOCLAX / AZACITIDINEPRINCESS MARGARET CANCER CENTREPending
Jun 29, 2021A phase II open-label study of combined ruxolitinib and enasidenib in patients with accelerated/blast-phase myeloproliferative neoplasm or chronicphase…ENASIDENIBPRINCESS MARGARET CANCER CENTREOngoing
Feb 17, 2021A phase 3, double-blind, randomized study to compare the efficacy and safety of luspatercept (ace-536) versus placebo in subjects with myeloproliferative…REBLOZYL (LUSPATERCEPT FOR INJECTION)Bristol-Myers SquibbOngoing
Dec 30, 2019A phase 2 pilot randomized controlled trial assessing feasibility of thromboprophylaxis with apixaban in jak2-positive myeloproliferative neoplasm patientsAPIXABANOTTAWA HOSPITAL RESEARCH INSTITUTEClosed

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.